The Lillehei-Kaster aortic valve prosthesis

Diamond Anniversary of Mechanical Cardiac Valve Prostheses: A Tale of Cages, Balls, and Discs

This year marks the 60th anniversary of the first aortic and mitral valve replacements using mechanical artificial prosthesis. The first caged-ball devices represented a milestone in cardiac surgery and in the treatment of valvular disease. The following decades witnessed a great evolution in mechanical valve technology providing, through frustrating complications and stimulating successes, more reliable models to be safely used in the clinical setting. This review pays tribute to pioneers of this field who made currently available the most advanced models of mechanical prostheses with extended records of durability and performance, to be used as reliable alternatives to biological devices.

Mechanical heart valves: 50 years of evolution

The past 50 years have witnessed remarkable progress in the development of safe, hemodynamically favorable mechanical heart valves. Starr-Edwards aortic and mitral ball valves introduced in the mid-1960s, continue to be used successfully worldwide. More than 100,000 Omniscience and Omnicarbon tilting-disc valves have been implanted since 1978 with essentially no mechanical failure; similar results have been obtained with more than 300,000 Hall-Kaster and Medtronic-Hall tilting-disc valves over the past 25 years. Pyrolytic carbon, originally used to encapsulate nuclear fuel rods, has been adapted for the fabrication of discs, leaflets and the housings for more than 2 million mechanical valves. The St. Jude bileaflet valves, totally fabricated from pyrolytic carbon, have remained virtually unchanged in design since their introduction in 1977. More than 1.3 million of these valves have been implanted worldwide with virtually no reported failures of the carbon leaflets or housings. Similarly, pyrolytic carbon bileaflet Carbomedics valves have been implanted in more than 500,000 patients since 1986. Now, 50 years after Dr Gibbon's seminal achievement, patients with debilitating valve disease can have elective valve replacement (mechanical or tissue) with an operative mortality approaching 1% to 2% and a low lifetime complication rate.

Advances in Heart Valve Surgery

Heart valve surgery continues to evolve in a dynamic fashion. While the exact role of minimally invasive approaches still needs to be defined, progress has been made in the development of new bioprostheses and their durability. Most importantly, valve repair has been standardized for the mitral and introduced for the aortic valve with results that have been superior to valve replacement. Selection of the optimal procedure for the individual patient is now facilitated. In the future, a wider application of repair procedures and further improvements of biologic valves can be anticipated not only to influence long-term results but also the decision-making process for conservative or surgical treatment.

Long-term follow-up of small (size 20 and 21) Medtronic-Hall aortic valve prostheses

BACKGROUND

Our goal was to study the long-term follow-up of patients having aortic valve replacement and to focus particularly on the patients receiving small prostheses.

METHODS

Four hundred twenty-eight Medtronic-Hall valves were implanted (156 size 20 or 21 mm, 149 size 22 or 23 mm, and 123 size 25 or 27 mm). Group 20-21 had a higher number of female patients, more associated coronary lesions, and more patients with aortic stenosis.

RESULTS

The actuarial survival rate at 8 years was 80% for group 20-21, 80% for group 22-23, and 76% for group 25-27 (p = not significant). In group 20-21, the actuarial event-free rates at 8 years were as follows: thromboembolic complications, 94%; prosthetic valve endocarditis, 99%; reoperation, 98%; and hemorrhagic complications, 78%. The only factors of prognostic value in this group were age and associated coronary lesions.

CONCLUSIONS

The durable nature of the results obtained with the Medtronic-Hall 20- and 21-mm prostheses compared with large-diameter prostheses allows the use of a simple and reliable surgical technique and should mean that indications for ring enlargement become rare.

Up to thirty-year survival after aortic valve replacement in the small aortic root

Aortic valve replacement (AVR) in the small aortic root has been reported to be associated with obstruction of left ventricular output. This study was designed to investigate the determinants of long-term survival after the implantation of small size prostheses. From September 1961 to December 1993, 2,977 patients underwent isolated aortic valve replacement at our institution. Of these patients, 447 who were older than 18 years received small size (21 mm or less) prostheses. Long-term survival was investigated in the 404 patients who survived operation (more than 30 days) with 92% follow-up completeness (mean +/- deviation 7.1 +/- 6.4; maximum, 31 years). The age was younger than 50 years in 62 patients, 50 to 59 years in 60, 60 to 69 years in 99, 70 to 79 years in 138, and 80 to 94 years in 45; 67% were men. Thirty patients (7%) had previous AVR. Prosthesis usage included early Starr-Edwards models in 130 (32%), current Starr-Edwards (model 1260 since 1969) in 50 (12%), Carpentier-Edwards (porcine) in 113 (28%), and other prostheses in 111 patients (27%). One hundred sixteen patients (26%) had concomitant coronary artery bypass grafting (CABG). Eleven variables (age divided as above, sex, preoperative functional class, body surface area [BSA], small BSA [less than 1.6, 1.7, 1.8, or 1.9 m2], period of operation, previous AVR, type of prosthesis, size of prosthesis, concomitant CABG, and re-replacement) were investigated with regard to the long-term survival by the Kaplan-Meier method, and age, concomitant CABG, and type of prosthesis were significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Aortic dissection after aortic valve replacement: incidence and consequences for strategy

From 1986 to 1994, 10 patients were observed to have developed an acute aortic dissection at some stage after an aortic valve replacement (AVR). Study of the characteristics of these patients showed that all patients had an aortic diameter of 50 mm or more (range 50 to 80 mm, mean 64 mm), and 70% suffered from systemic hypertension. Subsequently, the echocardiographic database, containing data from 33,105 studies in 21,484 patients, was searched for cases of AVR in which an accurate aortic dimension could be measured. Of 524 patients who had undergone AVR, an accurate aortic diameter was recorded in 419. Thirty-seven patients had an aortic size greater than 50 mm. All acute dissections occurred in this group of patients. The incidence of acute dissections among patients with significant aortic dilatation following AVR was 27%, whereas the overall incidence of acute dissection after AVR is 0.6%. Although there was a preponderance of tilting disc mechanical valves in the dissecting patients, the type of valve implanted does not seem to be of any importance. From these observations, we conclude that implantation of a valved conduit is indicated even in the presence of mild annuloaortic ectasia (aortic size = 50 mm). Patients who have had an AVR and show an enlarging aortic diameter exceeding 50 mm should have an elective reoperation at an early stage, especially when systemic hypertension is present.

Survival and valve failure after aortic valve replacement

A prospective evaluation of 412 consecutive patients undergoing isolated aortic valve replacement between January 1982 and December 1985 was performed in an attempt to identify the determinants of survival and valve failure. A variety of valves were inserted to permit a prospective evaluation of alternative valves including: Björk-Shiley mechanical (n = 37), Ionescu-Shiley pericardial (n = 261), Hancock pericardial (n = 78), and Carpentier-Edwards porcine (n = 36). Thirteen patients died in the hospital (3.2%) and 47 patients died in the follow-up period producing an actuarial survival of 81% +/- 3% at 48 months. Survival was independently predicted by advancing age, preoperative New York Heart Association functional class, and the presence of endocarditis (p less than 0.05 by Cox regression analysis). The majority of patients were symptomatically improved (New York Heart Association class I or II: 21% preoperative, 88% postoperative). Freedom from structural valve dysfunction, prosthetic valve endocarditis, and reoperation for valve-related complications were 95% +/- 2%, 95% +/- 2%, and 92% +/- 2% at 48 months, respectively. These valve-related complications occurred more frequently in younger patients and in those with a Hancock pericardial valve (freedom from structural valve dysfunction, 89% +/- 5%; prosthetic valve endocarditis, 84% +/- 9%; reoperation, 78% +/- 10%; p less than 0.05 by Cox regression). Freedom from thromboembolism was 88% +/- 2% at 48 months; it was significantly lower in patients with a preoperative thromboembolic event and was not influenced by the type of prosthesis inserted. Freedom from anticoagulant-related hemorrhage was 85% +/- 8% at 48 months and was not influenced by any preoperative factors.(ABSTRACT TRUNCATED AT 250 WORDS)

Eight years' experience with the Medtronic-Hall valve prosthesis

During the period January 1981 to September 1986, 444 Medtronic-Hall heart valve prostheses were implanted in 351 patients (mean age, 45 +/- 10 years) mainly for rheumatic valve disease (63.2%). Most of the patients were in New York Heart Association functional class III. Concomitant surgical procedures, mainly conservative tricuspid or mitral procedures or coronary artery bypass grafting, were performed in 101 patients (28.7%). Single-valve replacement was performed in 262 patients (74.6%) (aortic in 117 patients, mitral in 143, and tricuspid in 2), double-valve replacement in 85 (24.2%) (mitral and aortic in 83 and mitral and tricuspid in 2), and triple-valve replacement in 4 (1.1%). Hospital mortality was 6.2%. Follow-up was 97.7% complete. The overall actuarial 8-year survival rate was 77.2%. The linearized incidence of valve-related complications was as follows: thromboembolism, 1.5%/patient-year; reoperation, 1.5%/patient-year; endocarditis, 1.25%/patient-year; hemolysis, 0.52%/patient-year; anticoagulant-related hemorrhage, 0.39%/patient-year; and noninfection-related paraprosthetic leak, 0.33%/patient-year. There were no instances of structural failure. We conclude that after 8 years of follow-up, the Medtronic-Hall valve prosthesis has an excellent clinical performance and a low range of valve-related complications.

Twenty-five-year review of the Magovern-Cromie sutureless aortic valve

We reviewed 25 years (4,798 patient-years) of aortic valve replacement with the Magovern-Cromie sutureless valve. Operative mortality was 11% for isolated aortic valve replacement and 15% for aortic valve replacement with concomitant cardiac procedures. Since 1981, operative mortality has declined to 4.9%. Valve-related morbidity was in the lower expected ranges for prosthetic aortic valves: ball variance, 0.3%/patient-year; paraprosthetic leak, 0.41%/patient-year; valve endocarditis, 0.43%/patient-year; valve thrombosis, 0.04%/patient-year; and embolic events, 3.95%/patient-year. The incidence of aortic valve reoperation was 0.76%/patient-year. The 5-year, 10-year, and 20-year probability of survival corrected for normal mortality was 77%, 64%, and 52% for all discharged patients. This review confirms the Magovern-Cromie valve to be a safe, durable, and efficient prosthetic valve.